Gracell Biotechnologies to Participate in Truist Securities Cell Therapy Symposium
20 Junho 2023 - 9:30AM
Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ:
GRCL), a global clinical-stage biopharmaceutical company dedicated
to developing innovative and highly efficacious cell therapies for
the treatment of cancer and autoimmune diseases, today announced
that the management team will participate and host investor
meetings in the Truist Securities Cell Therapy Symposium:
Symposia-cel on June 27, 2023, in New York, NY.
For more information, please visit ir.gracellbio.com.
About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a
global clinical-stage biopharmaceutical company dedicated to
discovering and developing breakthrough cell therapies. Leveraging
its pioneering FasTCAR and TruUCAR technology platforms and SMART
CAR™ technology module, Gracell is developing a rich clinical-stage
pipeline of multiple autologous and allogeneic product candidates
with the potential to overcome major industry challenges that
persist with conventional CAR-T therapies, including lengthy
manufacturing time, suboptimal cell quality, high therapy cost, and
lack of effective CAR-T therapies for solid tumors and autoimmune
disease. For more information on Gracell, please visit
www.gracellbio.com. Follow @GracellBio on LinkedIn.
Media contacts
Marvin Tang
marvin.tang@gracellbio.com
Jessica Laub
jessica.laub@westwicke.com
Investor contacts
Gracie Tong
gracie.tong@gracellbio.com
Stephanie Carrington
stephanie.carrington@westwicke.com
Gracell Biotechnologies (NASDAQ:GRCL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Gracell Biotechnologies (NASDAQ:GRCL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024